Lurasidone, sold as Latuda, was approved by the FDA in 2010 for schizophrenia and in 2013 for bipolar I depression. It has become a popular atypical antipsychotic in part because of its favourable metabolic profile — patients tend to gain less weight, and have less impact on blood sugar and lipids, than on most other antipsychotics. Like ziprasidone, it has a meal requirement that is essential to its effectiveness.
Lurasidone is a once-daily atypical antipsychotic with one of the cleanest metabolic profiles in the class — but absorption depends on taking it with a meal of at least 350 calories.
What lurasidone is
Lurasidone is a benzisothiazol derivative that combines D2 dopamine antagonism with potent 5-HT2A and 5-HT7 antagonism, plus 5-HT1A partial agonism. The 5-HT7 blockade is one of its more distinctive features and is hypothesised to contribute to its mood and cognitive effects. The full FDA prescribing information is available through Drugs@FDA.
What it treats
- Schizophrenia in adults and adolescents (ages 13 and up)
- Depressive episodes in bipolar I disorder — both as monotherapy and as adjunct to lithium or valproate, in adults and children ages 10 and up
The bipolar depression indication is particularly important: very few medications are approved specifically for bipolar depression, and lurasidone has good evidence in that space.
Typical dosing range
FDA-labelled adult dosing ranges from 20 to 160 mg per day for schizophrenia, and 20 to 120 mg for bipolar depression, given once daily with food. Initial doses are typically lower (20–40 mg) and titrated upwards. Specific dosing should come from your prescriber.
The food requirement
Lurasidone's absorption is roughly doubled when taken with a meal of at least 350 calories. Without food, blood levels can drop substantially, leading to subtherapeutic dosing. The label is explicit on this, and patients are usually advised to take it with dinner. As with ziprasidone, planning around meals is part of starting lurasidone successfully.
Common side effects
- Akathisia — moderately common, especially at higher doses
- Nausea, dyspepsia
- Sedation — moderate
- Extrapyramidal symptoms (parkinsonism, dystonia) — possible, dose-related
- Insomnia or anxiety
- Mild prolactin elevation
Notably, lurasidone is among the more metabolically neutral atypicals — average weight gain is small, and blood sugar and lipid changes are minimal compared to olanzapine, quetiapine, or clozapine.
Serious side effects
High fever with muscle rigidity (possible neuroleptic malignant syndrome); persistent involuntary movements (possible tardive dyskinesia); severe akathisia; suicidal thoughts; severe rash.
- Tardive dyskinesia (long-term risk, lower than first-generation antipsychotics)
- Neuroleptic malignant syndrome (rare)
- Boxed warning for increased mortality in elderly with dementia-related psychosis
- Boxed warning for increased suicidality in young adults treated for depression
Drug interactions
Lurasidone is heavily metabolised by the liver enzyme CYP3A4. Strong inhibitors (some antifungals, certain antibiotics, grapefruit juice) and strong inducers (some seizure medications, rifampin, St. John's Wort) significantly affect its blood levels and may make it inappropriate. This is worth reviewing with your prescriber if you are on other medications.
What patients commonly say
- "It worked for my bipolar depression when nothing else had."
- "I didn't gain weight, which mattered enormously to me."
- "Eating dinner with the dose was a small adjustment."
- "I had restlessness on the higher dose; we lowered it and that helped."
Questions for your prescriber
- How will I make sure I take it with a sufficient meal?
- Are any of my other medications going to interact?
- What's the target dose and how quickly will we get there?
- If I get akathisia, what can we try?
- How will we monitor for tardive dyskinesia long-term?
Putting it together
Lurasidone is one of the more popular atypicals because it does what people often want: control symptoms without the metabolic cost. Its bipolar depression approval is a meaningful gap-filler in psychiatric practice. The food requirement and CYP3A4 sensitivity are real but manageable considerations.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.